Clinical Trial Update: Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating angiotensin-neprilysin inhibition in diastolic dysfunction after myocardial infarction has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diastolic Dysfunction
• Myocardial Infarction

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Jacob Moller | Conditions: Myocardial Infarction, Diastolic Dysfunction | Phase 2 | Status: TERMINATED